When An SPA Is Not Enough: FDA Will Consider Response Rate For Allos Drug
Executive Summary
The trial supporting the NDA for Allos Therapeutics' peripheral T-cell lymphoma drug pralatrexate was conducted under a Special Protocol Assessment with FDA - but that does not necessarily mean the magnitude of benefit shown will satisfy the agency
You may also be interested in...
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma
Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn
Allos gains its first U.S. indication with the accelerated approval of Folotyn (pralatrexate) in peripheral T-cell lymphoma.